# Ann DeWitt

> Ann DeWitt is a seed investor at Springboard Enterprises backing Biotechnology and Health Care. See 24 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Springboard Enterprises](https://shizune.co/investors/profile/springboard-enterprises)
- Location: Boston, United States
- Total investments: 24
- Last investment: Mar 2026
- Lead investor: 46%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ann-dewitt-4772704

Ann DeWitt is a seed investor at Springboard Enterprises in Boston focused on Biotechnology and Health Care. Ann DeWitt is the General Partner of The Engine. She is a former COO at The Engine. She attended Harvard Business School, Massachusetts Institute of Technology, and University of Illinois Urbana-Champaign.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 29% |
| Health Care | 4 | 17% |
| Medical | 2 | 8% |
| Big Data | 2 | 8% |
| Health Diagnostics | 2 | 8% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 29% |
| Series A | 6 | 25% |
| Series B | 2 | 8% |
| Pre-Seed | 1 | 4% |
| Series C | 1 | 4% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $50M | Series C | Mar 26, 2026 |  |
| Bexorg | Bexorg is a techbio company that supports central nervous system drug discovery and development. The company uses its proprietary wet-lab platform, BrainEx, to generate human brain data. It trains predictive models and creates an AI engine to facilitate drug discovery research. | $23M | Series A | Oct 15, 2025 |  |
| Predicta Biosciences | Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $23.4M | Series A | Oct 01, 2025 |  |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $9M | Venture - Series Unknown | Apr 09, 2025 |  |
| Kano Therapeutics | Kano Therapeutics focuses on the correction of gene-length DNA using circular single-stranded DNA biomaterials. The company provides a comprehensive platform that combines manufacturing, application, and computational tools for genetic payload development. This approach empowers researchers and organizations to advance genetic cures effectively andsafely. | $5M | Seed | Aug 12, 2024 |  |
| Predicta Biosciences | Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages. | $5.2M | Seed | Jul 16, 2024 |  |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $12M | Venture - Series Unknown | May 22, 2024 |  |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $9M | Venture - Series Unknown | Sep 13, 2023 |  |
| Droplet Biosciences | Droplet Biosciences can offer earlier and more accurate cancer diagnosis by using lymphatic fluid. | $8M | Seed | Mar 16, 2023 |  |
| Terrestrial Bio | Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration and a novel sustained release microneedle for improved vaccine delivery. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving productsfor people around the world. | $10M | Series B | Jan 10, 2023 |  |

10 of 24 investments shown.

## Co-investors
- [The Engine](https://shizune.co/investors/profile/the-engine-b5c2) — VC Fund, 15 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 6 deals together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 4 deals together
- [Blindspot Ventures](https://shizune.co/investors/profile/blindspot-ventures) — VC Fund, 4 deals together
- [Global Health Investment Corporation](https://shizune.co/investors/profile/global-health-investment-corporation-f967) — VC Fund, 4 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 4 deals together

## About Springboard Enterprises

VC Fund · Washington, United States

Springboard’s mission is to accelerate the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. We are a leading network of influencers, investors and innovators dedicated to building high-growth companies led by women who are transforming industries in technology and lifescience.The measure of our success is in the results. Since 2000, over 800 Springboard portfolio companies seeking financial and human capital for product development and expansion have created over $20B in value, are revenue generators and job creators. With 200 exits to strategic acquirers and 20 IPOs, Springboard Entrepreneurs are Transforming Industries.

5 contacts available at Springboard Enterprises.

| Name | Title | Profile |
| --- | --- | --- |
| Kay Koplovitz | Co-Founder and Chairman | https://shizune.co/investors/profile/kay-koplovitz |
| Natalie Buford-Young | Chief Executive Officer | https://shizune.co/investors/profile/natalie-buford-young |
| Amy Millman | Founder & President | https://shizune.co/investors/profile/amy-millman |
| Ann DeWitt | Life Sciences Council member | https://shizune.co/investors/profile/anne-dewitt |
| Juliana Garaizar | Life Science Council Member | https://shizune.co/investors/profile/juliana-garaizar |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Ann DeWitt invest in?

Ann DeWitt invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ann DeWitt last invest?

The most recent investment recorded for Ann DeWitt closed in Mar 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co